Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

(Reuters) - The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The generic drug ...

(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

The U.S. Food and Drug Administration's approval of Mylan N.V. MYL's generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a "clear negative" for Momenta ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

Copaxone franchise continues to be embroiled in litigations. However, it may not be easy for generic versions of Copaxone 40mg/ml to enter the market. Acquisition of Actavis Generics will further help ...